Replies to post #20234 on BLUE SKY BREAKOUT

[$Pistol Pete$]

$DFFN Breaking News DFFN



“We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”

http://investors.diffusionpharma.com/file/Index?KeyFile=391934667